New drug cocktail aims to shrink Hard-to-Treat breast tumors
NCT ID NCT07161791
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-phase study tests whether adding pirfenidone to standard immunotherapy (camrelizumab) and chemotherapy can shrink tumors in 12 people with advanced triple-negative breast cancer. Participants must have already tried first-line treatment. The goal is to see how many patients' tumors shrink or stabilize, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.